Clarivate Competitive Intelligence & Landscape
clarivate.com ·
Overview
Clarivate Overview
The company’s core products and services include enriched data, insights, and analytics, along with workflow solutions and expert services designed to accelerate innovation and reduce risk for its clients. Clarivate’s offerings encompass well-known brands like Web of Science, Cortellis, Derwent, and CPA Global, which serve over 43,000 universities, research institutions, corporations, and government agencies worldwide (Clarivate, Exa). Its target market primarily includes researchers, intellectual property professionals, and organizations involved in scientific research, patenting, and regulatory compliance.
With a workforce of approximately 7,563 employees as of early 2026, Clarivate emphasizes its mission of connecting people, data, and ideas to make the world’s innovation more impactful. The company's value proposition centers on providing trusted insights and analytics that help clients speed up the process of discovering, protecting, and commercializing new ideas, thereby fostering global innovation and scientific progress (Clarivate, Exa).
Clarivate Weekly Intel Updates
Receive weekly intel updates about Clarivate straight to your inbox.
Competitors
Clarivate Competitors
Clarivate serves high-stakes environments including universities, law firms, and R&D departments in global corporations, aiming to reduce the time from idea to market-ready product [5].
Several companies operate in the competitive landscape of Clarivate, offering similar services in intellectual property and data analytics.
Lighthouse IP, IPqwery, Quant IP, and InQuartik are identified as top competitors and alternatives [3].
Lighthouse IP, for instance, provides comprehensive global intellectual property data [3]. These companies compete by offering specialized data and analytics to support innovation and decision-making, often focusing on specific aspects of intellectual property management or research insights [3, 5].
While Clarivate offers a broad suite of products like Cortellis for drug discovery and competitive intelligence, and Derwent for patent analytics [1, 2], its competitors may differentiate themselves through specialized data coverage or unique analytical tools. For example, EndNote.com, another related entity, focuses specifically on reference management for researchers and students, aiding in organizing research and managing bibliographies [6]. The market positioning of these competitors varies, with some offering more niche solutions compared to Clarivate's extensive portfolio [3, 6].
The competitive landscape for Clarivate Analytics is dynamic, with various players vying for market share in the information services sector [4, 7].
Clarivate itself aims to stand out by merging domain knowledge with advanced technology [4]. Competitors like Lighthouse IP, IPqwery, Quant IP, and InQuartik present direct alternatives, each potentially offering distinct features, pricing models, and market share within the intellectual property data domain [3]. Understanding these differences is key for businesses seeking the most suitable data and analytics solutions for their innovation and research needs [7].
Sources
Competitive intelligence
clarivate.com
Cortellis Pharma Competitive Intelligence
clarivate.com
Clarivate Analytics Competitors & Alternatives
datarade.ai
Clarivate Analytics: Business Model, SWOT Analysis, and ...
pitchgrade.com
Clarivate Reviews, Pricing, Features & Alternatives in 2026 | Nerdisa
nerdisa.com
Top clarivate.com competitors & alternatives - AhrefsTop
ahrefs.com
What is Competitive Landscape of Clarivate Analytics Company? – CanvasBusinessModel.com
canvasbusinessmodel.com
Clarivate Analytics PLC (Form: F-4, Received: 02/27/2019 06:51:54)
content.edgar-online.com
Product & Pricing
Clarivate Product and Pricing Intelligence
Regarding pricing, Clarivate's software and analytics solutions have a median annual cost of approximately $175,931, with variations depending on the specific product and tier of service (vendr.com). While detailed tiered plans and free features are not explicitly listed, Clarivate generally offers tailored pricing based on client needs, often requiring direct contact for precise quotes. Recent updates indicate a strategic shift towards subscription-based access, especially in academic sectors, emphasizing flexible, scalable plans (clarivate.com). Overall, Clarivate’s offerings are designed to provide comprehensive insights with varying levels of access, supporting both small-scale and enterprise-level clients.
Sources
Pricetrack: Medtech product pricing & analysis - Clarivate
clarivate.com
Cortellis Generics & Products Intelligence - Clarivate
clarivate.com
Cortellis Product Intelligence Release Information - Clarivate
clarivate.com
MedTech Market Tracking Solutions - Clarivate
clarivate.com
Clarivate Analytics Software Pricing & Plans 2025 - Vendr
vendr.com
Clarivate Launches New Academic Access Strategy
clarivate.com
Competitive intelligence | Clarivate
clarivate.com
Pricing · File Histories and Document Services · Intellectual Property Solutions from Clarivate Analytics
filehistories.clarivate.com
Ad Campaigns
Clarivate Ad Campaigns
Clarivate is currently running 200 ads across Google — 200 on Google. Explore Clarivate's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.
See of Clarivate's ads
Browse the live creative across Google, Meta & LinkedIn in the ad library
Hiring & Layoffs
Clarivate Hiring and Layoffs
Recent hiring trends suggest that Clarivate is actively recruiting, especially in roles related to data analytics, research, and AI development, aligning with their strategic emphasis on innovation and proprietary solutions. The company’s focus on enhancing AI capabilities and developing new services indicates a forward-looking strategy aimed at maintaining its competitive edge in research and patent intelligence (PR Newswire).
Regarding layoffs, there are no recent reports or public disclosures indicating significant workforce reductions. Instead, Clarivate appears to be focusing on organic growth, operational efficiency, and expanding its offerings, which signals a strategic emphasis on strengthening its core business and exploring potential sales of certain segments, such as the Life Sciences & Healthcare division. Overall, their hiring patterns and financial results suggest a company committed to growth, innovation, and market expansion in 2026.
Leadership
Clarivate Management and Leadership Team
Sources
Clarivate Appoints Former ProQuest CEO Matti Shem Tov as the Company’s Next CEO | Clarivate
clarivate.com
Clarivate Announces Retirement of Chief Executive Officer Jerre Stead and Appointment of Jonathan Gear as New CEO | Clarivate
clarivate.com
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director | Clarivate
clarivate.com
Welcoming Bill Graff – the new Chief Information Officer for Clarivate
clarivate.com
Clarivate Announces Changes to Executive Leadership Team and Adds Chief Revenue Officer | Clarivate
clarivate.com
Jonathan Gear Assumes Chief Executive Officer Role for Clarivate with Jerre Stead Retirement | Clarivate
clarivate.com
Financials
Clarivate Financial Performance, Fundraising, M&A
Regarding fundraising and M&A activity, Clarivate is actively engaged in strategic reviews, including discussions to sell its Life Sciences & Healthcare business, indicating ongoing portfolio optimization efforts (PR Newswire). The company has also invested in proprietary assets and AI capabilities to enhance its service offerings, which support its financial health and growth prospects (Clarivate). Overall, Clarivate's financial health appears stable with a focus on organic growth, strategic portfolio adjustments, and leveraging AI technologies to sustain its market position (Clarivate).
Sources
Clarivate Reports Fourth Quarter and Full Year 2025 Results
prnewswire.com
Clarivate (CLVT) Turns Q4 Profit As Loss Reduction Narrative Faces ...
simplywall.st
Clarivate: Overview
ir.clarivate.com
Clarivate (NYSE:CLVT) - Earnings & Revenue Performance
simplywall.st
Clarivate PLC (CLVT) Q4 2025 Earnings Call Highlights
finance.yahoo.com
Clarivate Reports Fourth Quarter and Full Year 2025 Results
prnewswire.com
Clarivate Reports Q4 & FY 2024 Results
clarivate.com
Clarivate Plc Q4 2025 Earnings Call Summary
finance.yahoo.com
Partnerships
Clarivate Partnerships, Clients and Vendors
In terms of enterprise clients, Clarivate serves a diverse array of sectors including academia, government, healthcare, and intellectual property, with notable clients across these fields utilizing its extensive portfolio of products like Web of Science, Cortellis, Derwent Innovation, and IPfolio (clarivate.com). Its technology integrations include partnerships with AI-focused companies such as AI21 Labs, to incorporate generative AI into its research tools, and Iprova, to streamline invention workflows and patent processes (clarivate.com).
Furthermore, Clarivate maintains ecosystem relationships through collaborations with industry leaders in patent analytics, drug discovery, and market intelligence, exemplified by its integration of AI and data analytics to improve research outcomes and intellectual property management (clarivate.com). These strategic alliances and technology integrations position Clarivate as a key player in the global research and innovation ecosystem.
Sources
Clarivate & Iprova Partner to Streamline Invention Process
clarivate.com
Academia & Research Data Solutions - Clarivate
clarivate.com
Clarivate Partners with ALA to Advocate for U.S. Libraries
clarivate.com
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil | Clarivate
clarivate.com
Clarivate Announces Partnership with AI21 Labs as part of its Generative AI Strategy to Drive Growth | Clarivate
clarivate.com
Customer Stories - Clarivate
clarivate.com
Partner Identification And Deal-Making | Clarivate
clarivate.com
Clarivate - Wikipedia
en.wikipedia.org
Events
Clarivate Event Participations
Additionally, Clarivate organizes webinars and virtual roadshows, such as the one titled "The 2022 vision and beyond," which aimed to share insights on their strategic outlook and technological advancements in 2025 (Clarivate Webinars). They also participate in industry-specific conferences like Pharmavision India, where they discuss developments in life sciences and healthcare, further emphasizing their engagement in community and professional events (Clarivate Pharmavision India Conference).
Overall, Clarivate's involvement in these events underscores their commitment to thought leadership, networking, and advancing innovation across multiple sectors.
Sources
Event Calendar - Clarivate
ir.clarivate.com
Clarivate: Overview
ir.clarivate.com
Clarivate Announces 15th Annual Pharmavision India Conference Agenda | Clarivate
clarivate.com
Clarivate celebrates Ignite IP conference | Clarivate
clarivate.com
Clarivate Digital Roadshow - The 2022 vision and beyond | Clarivate
clarivate.com
Clarivate - Wikipedia
en.wikipedia.org
Press Releases - Clarivate
ir.clarivate.com
Clarivate Leadership Presents at Recent Investor Conferences | Clarivate
clarivate.com
Frequently Asked Questions
What does Clarivate's exploration of a Life Sciences & Healthcare division sale signal about their strategic direction?
Clarivate appears to be refocusing on its core IP and academic research businesses by shedding peripheral assets. The company is actively in discussions to sell its Life Sciences & Healthcare division as part of a broader portfolio optimization, a signal that management under new CEO Jonathan Gear is prioritizing depth in IP analytics and research intelligence over breadth across verticals. This mirrors a classic portfolio-rationalization playbook following a period of acquisition-led growth.
Is Clarivate's financial trajectory a genuine turnaround or still a warning sign for investors and counterparties?
The trajectory looks more like a fragile stabilization than a confirmed turnaround. Clarivate posted full-year 2025 revenue of approximately $2.455 billion and a Q4 net income of $3.1 million — a meaningful swing from significant prior-year losses — but its market capitalization of roughly $1.6 billion remains well below the revenue run-rate, implying the market still prices in execution risk. Earnings growth of 1.8% annually is modest given reported revenue growth of ~9.3%, suggesting margin conversion remains a work in progress.
What does Clarivate's recent CEO churn tell us about internal stability and strategic continuity?
The leadership sequencing raises legitimate continuity questions: Jerre Stead retired, Matti Shem Tov (former ProQuest CEO) was appointed in October 2024, and then Jonathan Gear assumed the CEO role — all within a relatively compressed window. Multiple CEO transitions in quick succession typically signal either a board-driven strategic reset or difficulty aligning on execution priorities. The parallel appointment of Gordon Samson as President of the Intellectual Property division suggests the board is reinforcing divisional leadership to provide operational stability beneath the C-suite churn.
What does Clarivate's hiring pattern in AI and data analytics roles suggest about their near-term product roadmap?
Clarivate is actively recruiting in AI development and data analytics, consistent with its announced partnership with AI21 Labs to embed generative AI into research tools and its integration with Iprova for patent workflow automation. This hiring pattern suggests the near-term roadmap centers on AI-augmenting existing flagship products — Web of Science, Derwent, Cortellis — rather than building net-new product lines, a lower-risk path to monetizing AI investment within the existing subscription base.
What do Clarivate's recent AI partnerships with AI21 Labs and Iprova reveal about their competitive positioning against pure-play AI research tools?
Rather than building foundational AI models in-house, Clarivate is pursuing a partnership-led AI strategy — integrating AI21 Labs' generative AI capabilities and Iprova's invention-workflow tooling into its existing data assets. This positions Clarivate as a data-and-workflow layer on top of third-party AI, which differentiates it from pure-play AI research tools like Semantic Scholar or Consensus that lack proprietary patent and citation datasets. The risk is that this approach creates dependency on partners and may be easier for competitors to replicate than a proprietary model would be.
What does Clarivate's median enterprise contract value of ~$175,000 annually suggest about their competitive vulnerability at the lower end of the market?
A median annual contract value of approximately $175,931 confirms Clarivate is priced as an enterprise solution, which leaves significant exposure to lower-cost alternatives — including freemium tools like Dimensions AI and Semantic Scholar — in budget-constrained academic and mid-market segments. Their announced shift toward a subscription-based access strategy for academia is likely a defensive move to defend seat count against these alternatives, though whether it expands or compresses average deal size is not yet clear from available data.
What does the CAPES partnership expansion in Brazil signal about Clarivate's international growth strategy?
The expanded landmark partnership with CAPES — Brazil's federal agency for graduate education — signals that Clarivate is actively deepening government-backed institutional relationships in emerging research markets rather than relying solely on organic growth in mature markets like the U.S. and Europe. This approach leverages Clarivate's Web of Science and related academic products as national-level research infrastructure, creating high-switching-cost, multi-year revenue streams that are difficult for competitors to displace.
How does Clarivate's workforce reduction to ~7,563 employees relate to its revenue base, and what does the ratio imply?
At approximately $2.455 billion in annual revenue and roughly 7,563 employees, Clarivate generates around $325,000 in revenue per employee — a reasonable ratio for a data-and-analytics business but not exceptional by SaaS standards. Given the company's focus on operational efficiency and the pending potential divestiture of its Life Sciences & Healthcare division, headcount is likely to shift further; a sale of that segment would reduce both revenue and employee count, potentially improving the ratio if the divested unit carries lower margins than the IP and academic core.
What does the appointment of Dr. Saurabh Saha as an independent director suggest about Clarivate's remaining commitment to life sciences even as it explores a segment sale?
The nomination of Dr. Saurabh Saha — a life sciences figure — to the board is an apparent tension with the reported exploration of selling the Life Sciences & Healthcare division. It could indicate that the board wants domain expertise during a sale process to maximize valuation and manage transition risk, or alternatively that the strategic review has not yet reached a definitive conclusion and life sciences remains a board-level priority. Corp-dev teams tracking this situation should watch whether Saha's appointment precedes a transaction announcement or a reversal of the divestiture narrative.
What competitive threat do Lighthouse IP, IPqwery, Quant IP, and InQuartik pose to Clarivate's IP analytics core?
These four competitors represent a fragmentation threat at the specialized end of the IP analytics market, potentially undercutting Clarivate's Derwent and related offerings on price and focus. However, none appears to match Clarivate's breadth of integrated data assets — patent, citation, regulatory, and drug pipeline — which is where Clarivate's defensibility lies. The more credible competitive risk is that enterprise customers increasingly assemble best-of-breed point solutions from these specialists rather than renewing broad Clarivate enterprise contracts, particularly as AI lowers the barrier to building bespoke analytics on top of raw patent data.
What does Clarivate's event strategy — including the Ignite IP conference and Pharmavision India — reveal about the verticals they are most actively defending?
Clarivate's investment in owned-event franchises like Ignite IP (intellectual property) and Pharmavision India (life sciences and pharma) signals these are the two verticals where it is most actively investing in community and thought leadership, consistent with the products — Derwent, Cortellis — that anchor those segments. Owned conferences are typically used to reinforce switching costs and deepen practitioner relationships in markets where the company faces competitive pressure; hosting them signals confidence that these segments remain core even as portfolio rationalization discussions continue.
Does Clarivate's partnership with the American Library Association signal a defense of the Web of Science franchise against open-access disruption?
Yes, the ALA partnership is best read as a relationship-investment to shore up Clarivate's standing with the academic library community — the primary buyer of Web of Science subscriptions — at a time when open-access mandates and free alternatives like Dimensions AI and Semantic Scholar are eroding the perceived necessity of paid research databases. Aligning publicly with the ALA on U.S. library advocacy positions Clarivate as a partner to libraries rather than a vendor extracting rent from them, a narrative shift that matters when institutional procurement committees are evaluating contract renewals.
Powered by ForesightIQ · Competitive intelligence from digital exhaust